193 related articles for article (PubMed ID: 27399926)
21. Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Tang H; Mourad S; Zhai SD; Hart RJ
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD008605. PubMed ID: 27901279
[TBL] [Abstract][Full Text] [Related]
22. [Peripartum cardiomyopathy].
Fennira S; Demiraj A; Khouaja A; Boujnah MR
Ann Cardiol Angeiol (Paris); 2006 Oct; 55(5):271-5. PubMed ID: 17078264
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study.
Sliwa K; Blauwet L; Tibazarwa K; Libhaber E; Smedema JP; Becker A; McMurray J; Yamac H; Labidi S; Struman I; Hilfiker-Kleiner D
Circulation; 2010 Apr; 121(13):1465-73. PubMed ID: 20308616
[TBL] [Abstract][Full Text] [Related]
24. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
25. The Use of Bromocriptine for Peripartum Cardiomyopathy after Twin Delivery via Oocyte Donation.
Morikawa N; Nakayoshi T; Yoshimura H; Watanabe M; Kumanomido J; Furusho A; Fukui D; Eto K; Nishida N; Nishihara M; A Kamiya C; Fukumoto Y
Intern Med; 2019 Feb; 58(4):541-544. PubMed ID: 30568125
[TBL] [Abstract][Full Text] [Related]
26. Dopamine agonist therapy in hyperprolactinemia.
Webster J
J Reprod Med; 1999 Dec; 44(12 Suppl):1105-10. PubMed ID: 10649819
[TBL] [Abstract][Full Text] [Related]
27. Peripartum cardiomyopathy: a rare cause of acute heart failure.
Vogel TCE; Schneiter S; Fehr T
BMJ Case Rep; 2022 Nov; 15(11):. PubMed ID: 36351676
[TBL] [Abstract][Full Text] [Related]
28. The effect of bromocriptine on left ventricular functional recovery in peripartum cardiomyopathy: insights from the BRO-HF retrospective cohort study.
Tremblay-Gravel M; Marquis-Gravel G; Avram R; Desplantie O; Ducharme A; Bibas L; Pacheco C; Couture E; Simard F; Poulin A; Malhamé I; Tran D; Rey E; Tournoux F; Harvey L; Sénéchal M; Bélisle P; Descarries L; Farand P; Pranno N; Diaz A; Afilalo J; Ly HQ; Fortier A; Jolicoeur EM;
ESC Heart Fail; 2019 Feb; 6(1):27-36. PubMed ID: 30565890
[TBL] [Abstract][Full Text] [Related]
29. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
Webster J
Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691
[TBL] [Abstract][Full Text] [Related]
30. Successful management of peripartum cardiomyopathy in a Kenyan setting: a case series.
Sonigra KJ; Nyambura E; Mwangi O; Sarna K; Omanwa K
Pan Afr Med J; 2023; 44():150. PubMed ID: 37396700
[TBL] [Abstract][Full Text] [Related]
31. Peripartum cardiomyopathy, place of drug therapy, assist devices, and outcome after left ventricular assistance.
Hamdan R; Nassar P; Zein A; Issa M; Mansour H; Saab M
J Crit Care; 2017 Feb; 37():185-188. PubMed ID: 27776335
[TBL] [Abstract][Full Text] [Related]
32. Peripartum cardiomyopathy-diagnosis, management, and long term implications.
Stergiopoulos K; Lima FV
Trends Cardiovasc Med; 2019 Apr; 29(3):164-173. PubMed ID: 30111492
[TBL] [Abstract][Full Text] [Related]
33. Comment On: Peripartum Cardiomyopathy Treatment with Dopamine Agonist and Subsequent Pregnancy with a Satisfactory Outcome.
Triebel J; Clapp C; Bertsch T
Rev Bras Ginecol Obstet; 2016 Nov; 38(11):580-582. PubMed ID: 27875851
[No Abstract] [Full Text] [Related]
34. Peripartum cardiomyopathy.
Mishra VN; Mishra N; Devanshi
J Assoc Physicians India; 2013 Apr; 61(4):268-73. PubMed ID: 24482966
[TBL] [Abstract][Full Text] [Related]
35. Peripartum cardiomyopathy: a review.
Bhattacharyya A; Basra SS; Sen P; Kar B
Tex Heart Inst J; 2012; 39(1):8-16. PubMed ID: 22412221
[TBL] [Abstract][Full Text] [Related]
36. Peripartum Cardiomyopathy.
Arany Z; Elkayam U
Circulation; 2016 Apr; 133(14):1397-409. PubMed ID: 27045128
[TBL] [Abstract][Full Text] [Related]
37. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
Biller BM; Molitch ME; Vance ML; Cannistraro KB; Davis KR; Simons JA; Schoenfelder JR; Klibanski A
J Clin Endocrinol Metab; 1996 Jun; 81(6):2338-43. PubMed ID: 8964874
[TBL] [Abstract][Full Text] [Related]
38. [Long-term treatment with cabergoline in pregnancy and neonatal outcome: report of a clinical case].
de Turris P; Venuti L; Zuppa AA
Pediatr Med Chir; 2003; 25(3):178-80. PubMed ID: 14601234
[TBL] [Abstract][Full Text] [Related]
39. Impact of autoantibodies against the M2-muscarinic acetylcholine receptor on clinical outcomes in peripartum cardiomyopathy patients with standard treatment.
Ma G; Chen L; Yue Y; Liu X; Wang Y; Shi C; Song F; Shi W; Lo Y; Zhang L
BMC Cardiovasc Disord; 2021 Dec; 21(1):619. PubMed ID: 34963460
[TBL] [Abstract][Full Text] [Related]
40. A global perspective on the management and outcomes of peripartum cardiomyopathy: a systematic review and meta-analysis.
Hoevelmann J; Engel ME; Muller E; Hohlfeld A; Böhm M; Sliwa K; Viljoen C
Eur J Heart Fail; 2022 Sep; 24(9):1719-1736. PubMed ID: 35778990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
